Acrivon Therapeutics reported positive interim data for ACR-368 in endometrial cancer and appointed Dr. Mansoor Raza Mirza as CMO. Acrivon Therapeutics, Inc. reported promising data from its ACR-368 ...
As radiology practices work toward and attest to the program's compliance goals, participation in ARCH-AI can help them implement safer and more effective AI products while helping radiologists ...
The ACR-368-tailored OncoSignature assay is being used to predict patients most likely to respond to ACR-368 in Acrivon’s ongoing, registrational-intent, multicenter Phase 2b trial of ACR-368 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results